Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032601 | 0.88 | ALDH1A1 (0.40) | PTPN1ALDH1A1ERN1KDM4E | |
| SCHEMBL19810818 | 0.83 | ALDH1A1 (0.49) | ALDH1A1ERN1L3MBTL1CA12CA1 | |
| SCHEMBL14679006 | 0.83 | ERN1 (0.40) | PTPN1ALDH1A1ERN1KDM4EL3MBTL1 | |
| SCHEMBL17786204 | 0.83 | ALDH1A1 (0.40) | ALDH1A1ERN1KDM4EL3MBTL1CA12 | |
| SCHEMBL275702 | 0.81 | TDP1 (0.44) | PTPN1ALDH1A1ERN1KDM4EL3MBTL1 | |
| SCHEMBL275754 | 0.81 | ERN1 (0.39) | ALDH1A1ERN1KDM4EL3MBTL1CA12 | |
| SCHEMBL1054616 | 0.81 | ERN1 (0.39) | ALDH1A1ERN1KDM4ECA12CA1 | |
| SCHEMBL1201100 | 0.80 | ALDH1A1 (0.48) | ALDH1A1ERN1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL29722800 | 0.80 | ALDH1A1 (0.48) | ALDH1A1ERN1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL1056366 | 0.80 | ALOX5AP (0.36) | CA12CA1CA9ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001309-B | Bis (sulfonamide) derivatives and their use as MPGES inhibitors | 格辛塔制药公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3224253-B1 | BIS (SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | ACTURUM REAL ESTATE AB (SE) | 2018-09-25 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | GESYNTA PHARMA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| EP-3224253-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Real Estate AB (SE) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016085392-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | Acturum Life Science AB (SE) | 2016-06-02 | — | — | WO | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | PTPN1 2861/4885ALDH1A1 553/4885ERN1 3895/4885 |
| US-10081614-B2 | Bis(sulfonamide) derivatives and their use as mPGES inhibitors | PTGES, PTGS1, PTGES2 | PTPN1 859/4885ALDH1A1 394/4885ERN1 1744/4885 |
| US-20170313672-A1 | BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS | PTGES, PTGS1, PTGES2 | PTPN1 859/4885ALDH1A1 394/4885ERN1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.